Krystal Biotech, Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDKrystal Biotech, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 89), indicating clear outperformance against the broad market. Earnings growth of 53% provides fundamental context to the price action. Momentum will need to be maintained above the 50-day moving average to sustain this leadership phase.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $313.74 | +9.46% | ABOVE |
| 50 SMA | $295.73 | +16.13% | ABOVE |
| 100 SMA | $279.78 | +22.75% | ABOVE |
| 150 SMA | $267.63 | +28.32% | ABOVE |
| 200 SMA | $245.16 | +40.09% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is KRYS in an uptrend right now?
KRYS has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, KRYS is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is KRYS overbought or oversold?
KRYS's RSI (14) is 73. The stock is in overbought territory (RSI > 70), which may signal a pullback.
Is KRYS outperforming the market?
KRYS has a Relative Strength (RS) Rating of 89 out of 99. Yes, KRYS is a market leader, outperforming 89% of all stocks over the past 12 months.
Where is KRYS in its 52-week range?
KRYS is trading at $343.43, which is 96% of its 52-week high ($356.50) and 94% above its 52-week low ($130.50).
How volatile is KRYS?
KRYS has a Beta of 0.89 and 52-week volatility of 39%. It's less volatile than the S&P 500 - generally more stable.